A PHASE I-II STUDY EVALUATING THE MURINE ANTI-IL-2 RECEPTOR ANTIBODY 2A3 FOR TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE
Authors:
- 1 July 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 50 (1) , 49-61
Abstract
A murine IgG1 antibody specific for the IL-2-binding site on the human lymphocyte IL-2 receptor β chain (CD25) was evaluated in 11 patients who developed acute graft-versus-host disease following allogeneic marrow transplantation. All patients had received cyclosporine and methotrexate for prophylaxis of GVHD, either alone (4 cases), or in combination with antithymocyte globulin (4 cases) or with prednisone (3 cases). Patients had developed GVHD at 7–53 days (median 12) after transplantation and had failed treatment with corticosteroids for 3–44 days (median 19). Residual GVHD was of grade II severity in 4 patients, grade III in 5 patients, and grade IV in 2 patients. Sequential patients received monoclonal antibody in escalating doses from 0.1 mg/kg/day to 1.0 mg/kg/day for 7 days. Side effects were fever, respiratory distress, hypertension, hypotension, and chills occurring in 11 of 72 (14%) antibody infusions. Trough antibody levels greater than 6 μg/ml were achieved in patients treated with 0.5 or 1.0 mg/ kg/day. Four of eight evaluable patients had an IgM antibody response, and one had an IgG response to the murine immunoglobulin. Clinical response of GVHD was evaluated in 10 patients who received the entire course of the antibody treatment. Among 7 patients treated within 40 days from transplantation, one patient had a complete response in the skin as the only involved organ, and 3 patients had a partial response, 2 in the skin and one in the gastrointestinal tract. No responses were achieved with liver disease at anytime or in any organ in patients treated beyond 40 days after transplantation. Since administration of this antibody was well tolerated and some efficacy was observed in patients with acute GVHD treated early after transplantation, there is a rationale for testing this antibody as an agent for prophylaxis of GVHD.Keywords
This publication has 11 references indexed in Scilit:
- Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody.The Journal of Immunology, 1986
- MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA - METHOTREXATE ALONE COMPARED WITH A COMBINATION OF METHOTREXATE AND CYCLOSPORINE FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE1986
- Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.Proceedings of the National Academy of Sciences, 1986
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Quantitative measurement of human interleukin 2 receptor levels with intact and detergent-solubilized human T-cellsMolecular Immunology, 1985
- Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporineThe American Journal of Medicine, 1985
- Fatal Epstein-Barr-Virus-Associated Proliferation of Donor B Cells After Treatment of Acute Graft-Versus-Host Disease with a Murine Anti-T-Cell AntibodyAnnals of Internal Medicine, 1984
- Transient expression of interleukin 2 receptors. Consequences for T cell growth.Journal of Experimental Medicine, 1983
- A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.The Journal of Immunology, 1981
- Selective in Vitro Growth of T Lymphocytes from Normal Human Bone MarrowsScience, 1976